Gadoterate meglumine - Guerbet

Drug Profile

Gadoterate meglumine - Guerbet

Alternative Names: DOTA-gadolinium meglumine; DOTA-Gd meglumine; Dotarem; Gadolinium-DOTA meglumine; Gd-DOTA meglumine; Magnescope

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Guerbet
  • Class Gadolinium-containing contrast agents; Heterocyclic compounds; Hexosamines; Macrocyclic compounds; Organometallic compounds; Sugar alcohols
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed CNS disorders; Vascular disorders

Most Recent Events

  • 28 Nov 2017 The Japanese Ministry of Health, Labour and Welfare (MHLW) announces its decision regarding the mandatory revision of the precautions section in the package insert of gadolinium-based contrast agents
  • 24 Oct 2017 Chemical structure information added
  • 05 Sep 2017 Registered for CNS disorders (Diagnosis, In infants, In neonates) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top